Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | PNP | P00491 | 2/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.47 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | HPRT1 | P00492 | 2/20 | 0.45 |
| ▸ | HINT1 | P49773 | 1/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13794857 | 0.87 | PNP (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| SCHEMBL9223878 | 0.84 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| SCHEMBL9223882 | 0.84 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| SCHEMBL852431 | 0.83 | PNP (0.50) | ADORA3PNPSTING1PDE3BPDE3A | |
| SCHEMBL24257989 | 0.82 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| SCHEMBL22110944 | 0.82 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| Entecavir Anhydrous SCHEMBL21510623 | 0.81 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| Entecavir Anhydrous SCHEMBL21347868 | 0.81 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| Entecavir Anhydrous SCHEMBL3436985 | 0.81 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A | |
| Entecavir Anhydrous SCHEMBL19644968 | 0.81 | ADORA3 (0.52) | ADORA3PNPSTING1PDE3BPDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200239513-A1 | LONG-ACTING PRODRUGS OF ENTECAVIR, PREPARING METHODS AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD (CN) | 2020-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239513-A1 | LONG-ACTING PRODRUGS OF ENTECAVIR, PREPARING METHODS AND USES THEREOF | ENTPD5, ENTPD1, TYMP | ADORA3 199/4885PNP 4/4885STING1 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.